ELITE PHARMACEUTICALS INC /NV/ 8-K

What Happened Elite Pharmaceuticals, Inc. (ELTP) filed a Form 8-K on April 2, 2026 under Regulation FD to announce the commercial launch of its generic methadone hydrochloride tablets in 5 mg and 10 mg strengths. The product is being marketed and sold under the Elite Laboratories, Inc. label. A press release announcing the launch was furnished as Exhibit 99.1 to the 8-K.

Key Details

• Announced date: April 2, 2026 (Form 8-K filing under Item 7.01 — Regulation FD Disclosure).
• Product: Generic methadone hydrochloride tablets, 5 mg and 10 mg.
• Label: Marketed and sold under the Elite Laboratories, Inc. label.
• Disclosure: Press release furnished as Exhibit 99.1 to the filing.

Why It Matters The launch expands Elite’s branded generic product portfolio into opioid dependency/pain management medication, which may increase product revenue opportunities if demand and reimbursement are favorable. For investors, this is a product-commercialization update rather than a financial report—there are no sales figures, earnings impacts, or guidance included in the filing.